Financhill
Buy
55

RGC Quote, Financials, Valuation and Earnings

Last price:
$16.16
Seasonality move :
-5.61%
Day range:
$13.14 - $18.15
52-week range:
$0.09 - $83.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
989.66x
Volume:
1.1M
Avg. volume:
168.1K
1-year change:
11076.46%
Market cap:
$7.9B
Revenue:
--
EPS (TTM):
-$0.33

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RGC
Regencell Bioscience Holdings Ltd.
-- -- -- -- --
HCM
HUTCHMED (China) Ltd.
-- -- -- -- $22.54
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
-- -- -- -- --
PRE
Prenetics Global Ltd.
$26M -- 265.18% -- $26.00
SBMFF
Sino Biopharmaceutical Ltd.
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RGC
Regencell Bioscience Holdings Ltd.
$16.00 -- $7.9B -- $0.00 0% --
HCM
HUTCHMED (China) Ltd.
$14.16 $22.54 $2.4B 5.28x $0.00 0% 4.09x
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
$0.81 -- $8.9M 8.18x $0.00 0% 0.75x
PRE
Prenetics Global Ltd.
$13.93 $26.00 $234.4M -- $0.00 0% 2.71x
SBMFF
Sino Biopharmaceutical Ltd.
$0.87 -- $15.6B 30.49x $0.01 1.32% 3.70x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RGC
Regencell Bioscience Holdings Ltd.
-- 21.200 -- --
HCM
HUTCHMED (China) Ltd.
7.07% 0.509 -- 4.41x
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
-- 0.000 -- --
PRE
Prenetics Global Ltd.
1.29% 4.220 1.18% 1.01x
SBMFF
Sino Biopharmaceutical Ltd.
23.1% 0.796 -- 1.14x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RGC
Regencell Bioscience Holdings Ltd.
-- -- -- -- -- --
HCM
HUTCHMED (China) Ltd.
-- -- 46.32% 50.64% -- --
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
-- -- -- -- -- --
PRE
Prenetics Global Ltd.
$14M -$6.6M -26.04% -26.74% -27.85% --
SBMFF
Sino Biopharmaceutical Ltd.
-- -- 6.83% 8.57% -- --

Regencell Bioscience Holdings Ltd. vs. Competitors

  • Which has Higher Returns RGC or HCM?

    HUTCHMED (China) Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- --
    HCM
    HUTCHMED (China) Ltd.
    -- -- $1.3B
  • What do Analysts Say About RGC or HCM?

    Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.54 which suggests that it could grow by 59.21%. Given that HUTCHMED (China) Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Regencell Bioscience Holdings Ltd..

    Company Buy Ratings Hold Ratings Sell Ratings
    RGC
    Regencell Bioscience Holdings Ltd.
    0 0 0
    HCM
    HUTCHMED (China) Ltd.
    9 2 1
  • Is RGC or HCM More Risky?

    Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.402%.

  • Which is a Better Dividend Stock RGC or HCM?

    Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGC or HCM?

    Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while HUTCHMED (China) Ltd.'s PE ratio is 5.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 4.09x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- -- --
    HCM
    HUTCHMED (China) Ltd.
    4.09x 5.28x -- --
  • Which has Higher Returns RGC or HKPD?

    Hong Kong Pharma Digital Technology Holdings Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Hong Kong Pharma Digital Technology Holdings Ltd.'s return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- --
    HKPD
    Hong Kong Pharma Digital Technology Holdings Ltd.
    -- -- --
  • What do Analysts Say About RGC or HKPD?

    Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than Hong Kong Pharma Digital Technology Holdings Ltd., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than Hong Kong Pharma Digital Technology Holdings Ltd..

    Company Buy Ratings Hold Ratings Sell Ratings
    RGC
    Regencell Bioscience Holdings Ltd.
    0 0 0
    HKPD
    Hong Kong Pharma Digital Technology Holdings Ltd.
    0 0 0
  • Is RGC or HKPD More Risky?

    Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock RGC or HKPD?

    Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings Ltd. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGC or HKPD?

    Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Hong Kong Pharma Digital Technology Holdings Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 0.75x for Hong Kong Pharma Digital Technology Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- -- --
    HKPD
    Hong Kong Pharma Digital Technology Holdings Ltd.
    0.75x 8.18x -- --
  • Which has Higher Returns RGC or PRE?

    Prenetics Global Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of -28.82%. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Prenetics Global Ltd.'s return on equity of -26.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- --
    PRE
    Prenetics Global Ltd.
    59.54% -$0.53 $163.3M
  • What do Analysts Say About RGC or PRE?

    Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 122.54%. Given that Prenetics Global Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Prenetics Global Ltd. is more attractive than Regencell Bioscience Holdings Ltd..

    Company Buy Ratings Hold Ratings Sell Ratings
    RGC
    Regencell Bioscience Holdings Ltd.
    0 0 0
    PRE
    Prenetics Global Ltd.
    1 0 0
  • Is RGC or PRE More Risky?

    Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock RGC or PRE?

    Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RGC or PRE?

    Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 2.71x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- -- --
    PRE
    Prenetics Global Ltd.
    2.71x -- $23.6M -$6.8M
  • Which has Higher Returns RGC or SBMFF?

    Sino Biopharmaceutical Ltd. has a net margin of -- compared to Regencell Bioscience Holdings Ltd.'s net margin of --. Regencell Bioscience Holdings Ltd.'s return on equity of -- beat Sino Biopharmaceutical Ltd.'s return on equity of 8.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- --
    SBMFF
    Sino Biopharmaceutical Ltd.
    -- -- $7.2B
  • What do Analysts Say About RGC or SBMFF?

    Regencell Bioscience Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Regencell Bioscience Holdings Ltd. is more attractive than Sino Biopharmaceutical Ltd..

    Company Buy Ratings Hold Ratings Sell Ratings
    RGC
    Regencell Bioscience Holdings Ltd.
    0 0 0
    SBMFF
    Sino Biopharmaceutical Ltd.
    0 0 0
  • Is RGC or SBMFF More Risky?

    Regencell Bioscience Holdings Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical Ltd. has a beta of 0.715, suggesting its less volatile than the S&P 500 by 28.542%.

  • Which is a Better Dividend Stock RGC or SBMFF?

    Regencell Bioscience Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical Ltd. offers a yield of 1.32% to investors and pays a quarterly dividend of $0.01 per share. Regencell Bioscience Holdings Ltd. pays -- of its earnings as a dividend. Sino Biopharmaceutical Ltd. pays out 65.96% of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios RGC or SBMFF?

    Regencell Bioscience Holdings Ltd. quarterly revenues are --, which are smaller than Sino Biopharmaceutical Ltd. quarterly revenues of --. Regencell Bioscience Holdings Ltd.'s net income of -- is lower than Sino Biopharmaceutical Ltd.'s net income of --. Notably, Regencell Bioscience Holdings Ltd.'s price-to-earnings ratio is -- while Sino Biopharmaceutical Ltd.'s PE ratio is 30.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings Ltd. is -- versus 3.70x for Sino Biopharmaceutical Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RGC
    Regencell Bioscience Holdings Ltd.
    -- -- -- --
    SBMFF
    Sino Biopharmaceutical Ltd.
    3.70x 30.49x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 62x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
63
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 40x

Alerts

Buy
54
SMX alert for Dec 5

SMX (Security Matters) Plc [SMX] is up 65.26% over the past day.

Sell
15
HOV alert for Dec 5

Hovnanian Enterprises, Inc. [HOV] is up 0.12% over the past day.

Buy
67
NUTX alert for Dec 5

Nutex Health, Inc. [NUTX] is down 0.53% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock